A bacterial toxin as a novel anti-cancer drug modulating the tumor-microenvironment

Area of Science:

• Oncology
• Immunology
• Microbiology

Background:

• Colorectal cancer (CRC) is a leading cause of cancer-related deaths globally.
• Current CRC treatments have significant side effects, necessitating novel therapeutic approaches.
• The tumor microenvironment (TME) plays a critical role in CRC progression and immune evasion.

Purpose of the Study:

• To evaluate the anticancer properties of MakA, a cytotoxin from Vibrio cholerae.
• To investigate MakA's effects on the TME and immune cell infiltration in a CRC mouse model.
• To assess MakA's safety and therapeutic potential for colorectal cancer.

Main Methods:

• Systemic administration of MakA in a mouse model of colorectal cancer.
• Analysis of tumor growth, cancer cell apoptosis, and immune cell infiltration in the TME.
• Assessment of leukocyte recruitment, activation, and production of pro-inflammatory mediators.

Main Results:

• MakA administration was found to be non-toxic and did not induce systemic tissue damage.
• MakA significantly suppressed tumor growth and promoted cancer cell apoptosis.
• MakA increased immune cell abundance, including neutrophils and macrophages, in the TME, enhancing anti-neoplastic immune responses.

Conclusions:

• MakA demonstrates significant anticancer properties by modulating the TME immune response.
• MakA enhances leukocyte recruitment and activation, contributing to anti-tumor effects.
• MakA represents a potential novel, less harmful therapeutic strategy for colorectal cancer.